AFP and hepatocellular carcinoma: The 1-year cumulative incidence of HCC were 0.6% (95% CI 0–1.7%) and 11.8% (95% CI 2.8–20.8%) for the groups with AFP level < 5.6 ng/mL and ≥ 5.6 ng/mL at the end of DAA therapy, respectively.